000151629 001__ 151629
000151629 005__ 20251017144616.0
000151629 0247_ $$2doi$$a10.3390/ph14080736
000151629 0248_ $$2sideral$$a126195
000151629 037__ $$aART-2021-126195
000151629 041__ $$aeng
000151629 100__ $$aGil Martínez V.
000151629 245__ $$aAntiviral therapeutic approaches for sars-cov-2 infection: A systematic review
000151629 260__ $$c2021
000151629 5060_ $$aAccess copy available to the general public$$fUnrestricted
000151629 5203_ $$aBackground: Due to the lack of an etiologic treatment for SARS-CoV-2 and the difficulties involved in developing new drugs, some drugs already approved for other diseases or with efficacy against SARS and MERS, have been used in patients with COVID-19. This systematic review aims to summarize evidence on the efficacy and safety of five antivirals applied to patients with COVID-19, that have proven to be effective either in vitro studies or in studies on SARS-CoV and MERS.; Methods: An intensive search of different databases (Pub Med, WoS, MEDLINE and Cochrane COVID-19 Study Register) has been carried out until the end of April 2021. This systematic review has been conducted according to the PRISMA statement. From each of the included studies, the characteristics of the intervention and comparison groups, demographic data and results were extracted independently; Results: Remdesivir is well tolerated and helps to accelerate clinical improvement but is ineffective in reducing mortality. Favipiravir is safe and shows promising results regarding symptom resolution but does not improve viral clearance. The use of lopinavir/ritonavir has been associated with an increased risk of gastrointestinal adverse events and it has not proven to be effective. No significant differences were observed between patients treated with ribavirin or umifenovir and their respective control groups; Conclusions: Remdesivir and favipiravir are well tolerated and effective in accelerating clinical improvement. This systematic review does not support the use of lopinavir/ritonavir, ribavirin and umifenovir in hospitalized patients with COVID-19.
000151629 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000151629 590__ $$a5.215$$b2021
000151629 591__ $$aPHARMACOLOGY & PHARMACY$$b69 / 279 = 0.247$$c2021$$dQ1$$eT1
000151629 591__ $$aCHEMISTRY, MEDICINAL$$b16 / 63 = 0.254$$c2021$$dQ2$$eT1
000151629 592__ $$a0.851$$b2021
000151629 593__ $$aPharmaceutical Science$$c2021$$dQ1
000151629 593__ $$aDrug Discovery$$c2021$$dQ1
000151629 594__ $$a4.0$$b2021
000151629 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000151629 700__ $$0(orcid)0000-0003-2153-0417$$aAvedillo Salas A.$$uUniversidad de Zaragoza
000151629 700__ $$0(orcid)0000-0002-1275-2600$$aSantander Ballestín S.$$uUniversidad de Zaragoza
000151629 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000151629 773__ $$g14, 8 (2021), 736 [26 pp.]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000151629 8564_ $$s7865682$$uhttps://zaguan.unizar.es/record/151629/files/texto_completo.pdf$$yVersión publicada
000151629 8564_ $$s2721561$$uhttps://zaguan.unizar.es/record/151629/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000151629 909CO $$ooai:zaguan.unizar.es:151629$$particulos$$pdriver
000151629 951__ $$a2025-10-17-14:19:40
000151629 980__ $$aARTICLE